NYSE: METMetlife Inc Stock
$78.66+0.63 (+0.81%)
Updated Dec 5, 2025
MET Price
$78.66
Fair Value Price
N/A
Market Cap
$51.83B
52 Week Low
$65.21
52 Week High
$88.09
P/E
14.73x
P/B
1.79x
P/S
0.76x
PEG
0.52x
Dividend Yield
2.86%
Revenue
$71.94B
Earnings
$3.84B
Gross Margin
25.7%
Operating Margin
6.82%
Profit Margin
5.1%
Debt to Equity
23.86
Operating Cash Flow
$15B
Beta
0.93
Next Earnings
Feb 4, 2026
Ex-Dividend
N/A
Next Dividend
Dec 9, 2025
MET Overview
MetLife Incorporated provides insurance, annuities, employee benefits, and asset management services worldwide. The company offers life, dental, group short-and long-term disability, individual disability, pet, accidental death and dismemberment, and vision isnurance products, as well as prepaid legal plans and administrative services-only arrangements for employers, among other services. It also provides fixed, indexed-linked, and variable annuities, and pension products. MetLife was founded in 1863 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MET's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Property & Casualty Insurance
Industry Rating
A
MET
Ranked#18 of 18
Ranked#18 of 18
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $33.72 | B | |
| $111.68 | B | |
| $6.89 | B |
Be the first to know about important MET news, forecast changes, insider trades & much more!
MET News
Overview
Due Diligence Score
–
Industry Average (40)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MET scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MET ($78.66) is trading below its intrinsic value of $87.64, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MET is good value based on its earnings relative to its share price (14.73x), compared to the US market average (46.7x)
P/E vs Market Valuation
MET is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more MET due diligence checks available for Premium users.
Valuation
MET price to earnings (PE)
For valuing profitable companies with steady earnings
Company
14.73x
Industry
14.69x
Market
46.7x
MET is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MET is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
MET price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.79x
Industry
1.49x
MET is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MET price to earnings growth (PEG)
For valuing profitable companies with growth potential
MET is good value based... subscribe to Premium to read more.
PEG Value Valuation
MET's financial health
Profit margin
Revenue
$17.4B
Net Income
$896.0M
Profit Margin
4.7%
MET's Earnings (EBIT) of $4.90B... subscribe to Premium to read more.
Interest Coverage Financials
MET's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$719.7B
Liabilities
$690.5B
Debt to equity
23.86
MET's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MET's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.6B
Investing
-$5.0B
Financing
-$508.0M
MET's operating cash flow ($14.63B)... subscribe to Premium to read more.
Debt Coverage Financials
MET vs Property & Casualty Insurance Stocks
Metlife Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.